POET Technologies Soars On Lumilens AI Deal And $400M Raise

POET Technologies Inc. surged as stocks have been trading up by 10.99 percent following highly positive technology partnership news.

Key Takeaways Traders Need To Know

Live Update At 12:32:50 EDT: On Monday, June 01, 2026 POET Technologies Inc. stock [NASDAQ: POET] is trending up by 10.99%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

POET Technologies is trading like a high‑beta AI hardware story, not a mature cash‑cow. The daily chart shows POET ripping from the single digits in early 2026/05 to recent closes in the low‑ to mid‑teens, with big swings around news. On 2026/06/01, POET opened near $11.98 and pushed to a $14.37 high before settling around $13.66 — a wide intraday range that tells you momentum traders are in control.

Intraday, POET’s 5‑minute action looks like a textbook trend day. Pre‑market liquidity built in the low $12s, then regular‑session trading drove a steady grind from the $12 handle toward the mid‑$13s and above. Pullbacks have been shallow and bought quickly, a sign of shorts getting squeezed and dip‑buyers active.

Under the hood, the fundamentals are early‑stage. Q1 2026 revenue was around $0.5M against a net loss above $12M, and ratios like price‑to‑sales north of 1,700 and deeply negative returns on equity scream “story stock.” At the same time, POET Technologies sits on strong liquidity — a current ratio above 35, low debt, and over $400M in cash and short‑term investments after the raise. For traders, that means runway is long, but the market is paying for future AI execution, not current earnings.

Why Traders Are Watching POET’s AI Story

The core reason POET Technologies is on every momentum screen right now is the Lumilens deal. This is not a tiny pilot order. The partnership targets wafer‑level photonic integration for frontier AI infrastructure — exactly where the market is pouring capital — with a $50M initial purchase order for POET’s Electrical‑Optical Interposer engines. Management is talking about that scaling above $500M over five years. For a company that just printed quarterly revenue in the hundreds of thousands, that’s a step‑change.

Traders reacted fast. Headlines around 2026/05/14 show POET Technologies ripping more than 30%–39% on heavy volume right after the Lumilens announcement. That kind of gap and run tells you funds and fast money are re‑rating the entire business model, not just bidding for a one‑day scalp. Still, moves that sharp rarely travel in a straight line. They often set up brutal shakeouts and intraday fake‑outs that punish traders who chase without a plan.

At the same time, POET Technologies has been busy tightening the execution story. The company is collaborating with LITEON and Lessengers, planning a U.S. redomiciling to sit closer to AI and data‑center customers, and hiring seasoned operator Dr. Sandeep Kumar as COO to build high‑volume manufacturing in Malaysia. That’s the classic shift from “science project” to “factory build‑out.”

But the market also reminded everyone that growth has a price. Just days after the AI euphoria, POET Technologies raised US$400M via a registered direct offering with a single institutional player, at about $21 per security — a small premium to market, plus three‑year warrants at a 25% premium strike. The stock dropped roughly 10% on that news, as traders weighed dilution and the risk of warrant overhang against the reality that POET now has capital to chase a 10x capacity expansion and M&A. The tug‑of‑war between long‑term AI optionality and near‑term supply overhang is exactly what active traders thrive on.

POET Technologies is now a pure trader’s stock: real AI‑linked orders, real dilution, real volatility. On one side, you have the Lumilens supply agreement that points to more than $500M of potential revenue over five years, plus new collaborations and a U.S. redomiciling aimed squarely at big AI and data‑center budgets. On the other side, the Q1 2026 numbers remind everyone that today’s revenue is tiny and losses are large, which means execution risk remains front and center.

The $400M capital raise, structured at a premium with performance‑linked warrants, tells you a serious institution is betting on POET Technologies. It also tells you common shareholders are sharing the bill through dilution and the prospect of more stock if warrants move in the money. How POET deploys that cash — into Malaysian manufacturing, R&D scale‑up, and light‑source acceleration — will decide whether the Lumilens headline turns into a durable revenue stream or just a hot press release.

For active traders, the playbook is simple but not easy. POET Technologies has the ingredients for big percentage moves in both directions: a hot AI narrative, early but visible demand, and a cap table reset that spooks weak hands. As Tim Sykes likes to say, “Volatile stocks are a gift if you study the news and cut losses quickly.” As Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.” POET is offering that exact education right now — and, as always, this is for educational and research purposes only, not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.